Inflammation predicts risk for cardiovascular disease (CVD) events, but the relation of drugs
that directly target inflammation with CVD risk is not established. Methotrexate is a disease …

The excess risk of cardiovascular disease (CVD) associated with inflammatory rheumatic
diseases has long been recognized. Patients with established rheumatoid arthritis (RA) or …

Objectives To examine in a nationwide cohort whether the risk of myocardial infarction (MI)
in patients with rheumatoid arthritis (RA) is comparable to the risk in patients with diabetes …

Introduction We analyzed the prevalence of cardiovascular (CV) disease in patients with
rheumatoid arthritis (RA) and its association with traditional CV risk factors, clinical features …

Context Although tumor necrosis factor (TNF)-α antagonists are increasingly used in place of
nonbiologic comparator medications, their safety profile remains incomplete. Objectives To …

Objective To examine the association of cardiovascular events with tumour necrosis factor
(TNF) α antagonist use compared with non-biological disease-modifying antirheumatic drug …

Background Though administrative databases are increasingly being used for research
related to myocardial infarction (MI), the validity of MI diagnoses in these databases has …

Objective We performed a systematic review and meta‐analysis to evaluate the comparative
effects of tumor necrosis factor inhibitors (TNF i), non‐TNF i biologics, and conventional …

Background Cardiovascular (CV) disease has a major impact on patients with rheumatoid
arthritis (RA), however, the relative contributions of traditional CV risk factors and markers of …

Objectives Rheumatoid arthritis (RA), along with glucocorticoid use, is associated with
cardiovascular disease. Cardiovascular safety of glucocorticoids in RA is controversial and …